Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
- Conditions
- Osteoarthritis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 360
- Registration Number
- NCT00171665
- Locations
- 🇺🇸
Montgomery Rheumatology Associates, Montgomery, Alabama, United States
🇺🇸Drug Research & Analysis Corp, Montgomery, Alabama, United States
🇺🇸Arizona Center for Clinical Research, Glendale, Arizona, United States
Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers
- Conditions
- Dyslipidemia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 120
- Registration Number
- NCT00171262
- Locations
- 🇪🇸
Novartis, Madrid, Spain
Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients
- Conditions
- Kidney Transplant
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 693
- Registration Number
- NCT00171496
VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 134
- Registration Number
- NCT00171067
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 265
- Registration Number
- NCT00171041
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E.Hanover, New Jersey, United States
Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 92
- Registration Number
- NCT00171756
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
- Conditions
- Persistent Nonvalvular Atrial Fibrillation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00171769
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery
- Conditions
- Cataract Surgery
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 62
- Registration Number
- NCT00170729
The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.
- Conditions
- DyspepsiaHeartburn
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00171457
- Locations
- 🇺🇸
Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
- Conditions
- Kidney Transplantation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novartis
- Registration Number
- NCT00170885
- Locations
- 🇨🇭
Novartis, Basel, Switzerland